Then, C. ; Herder, C. ; Then, H.* ; Thorand, B. ; Huth, C. ; Heier, M. ; Meisinger, C. ; Peters, A. ; Koenig, W.* ; Rathmann, W.* ; Roden, M.* ; Stumvoll, M.* ; Maalmi, H.* ; Meitinger, T.* ; Lechner, A. ; Scherberich, J.* ; Seissler, J.
Serum uromodulin is inversely associated with biomarkers of subclinical inflammation in the population-based KORA F4 study.
Clin. Kidney J. 14, 1618-1625 (2021)
Background: Uromodulin is a kidney-specific glycoprotein synthesized in tubular cells of Henle's loop exerting nephroprotective and immunomodulatory functions in the urinary tract. A small amount of uromodulin is also released into the systemic circulation, where its physiological role is unknown. Serum uromodulin (sUmod) has been associated with metabolic risk factors and with cardiovascular events and mortality, where these associations were partly stronger in men than in women. In this study, we investigated the associations of sUmod with biomarkers of subclinical inflammation in a population-based sample of women and men. Methods: Associations of sUmod with 10 biomarkers of subclinical inflammation were assessed in 1065 participants of the Cooperative Health Research in the Region of Augsburg (KORA) F4 study aged 62-81 years using linear regression models adjusted for sex, age, body mass index, estimated glomerular filtration rate and diabetes. Analyses were performed in the total study sample and stratified by sex. Results: sUmod was inversely associated with white blood cell count, high-sensitive C-reactive protein, interleukin (IL)-6, tumour necrosis factor-α, myeloperoxidase, superoxide dismutase-3, IL-1 receptor antagonist and IL-22 after multivariable adjustment and correction for multiple testing (P < 0.001 for each observation). There was a trend towards a stronger association of sUmod with pro-inflammatory markers in men than in women, with a significant P for sex interaction (<0.001) regarding the relation of sUmod with IL-6. Conclusions: sUmod was inversely associated with biomarkers of subclinical inflammation in older participants of the KORA F4 study. The association of sUmod with IL-6 differed between women and men. Future research should focus on whether the immunomodulatory properties of sUmod are one explanation for the association of sUmod with cardiovascular outcomes and mortality.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Immune Marker ; Immunology ; Serum Uromodulin ; Subclinical Inflammation ; Uromodulin; Tamm-horsfall Protein; Complement 1q; Glycoprotein; Risk; Antagonist; Activation; Mortality; Expression; Immunity
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2021
Prepublished im Jahr
HGF-Berichtsjahr
2021
ISSN (print) / ISBN
2048-8505
e-ISSN
2048-8513
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 14,
Heft: 6,
Seiten: 1618-1625
Artikelnummer: ,
Supplement: ,
Reihe
Verlag
Oxford University Press
Verlagsort
Great Clarendon St, Oxford Ox2 6dp, England
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30201 - Metabolic Health
30202 - Environmental Health
Forschungsfeld(er)
Genetics and Epidemiology
PSP-Element(e)
G-521500-002
G-504000-002
G-504000-006
G-502900-001
G-504000-010
G-504090-001
Förderungen
German Research Foundation (DFG)
Clinical Cooperation Group Diabetes, Ludwig-Maximilians-University Munchen
Helmholtz Zentrum Munchen
German Diabetes Centre
Federal Ministry of Health (Berlin, Germany)
Ministry of Culture and Science of the state North-Rhine Westphalia (Dusseldorf, Germany)
Helmholtz Zentrum Munchen-German Research Centre for Environmental Health - German Federal Ministry of Education and Research (BMBF)
State of Bavaria
German Federal Ministry of Education and Research (BMBF)
Deutsche Diabetes Gesellschaft (DDG)
Virtual Diabetes Institute (Helmholtz Zentrum Munchen)
Copyright
Erfassungsdatum
2021-07-23